All In Biotech

NDA 022004 · Azurity

Omnaris

Ciclesonide · Nasal

Novel

Last checked: Nov 20, 2026Latest source record: May 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 20, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

81

55 Phase 3, 1 recruiting

FAERS reports

4,999

4,577 serious, 264 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 8, 2022.

OMNARIS Nasal Spray is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older. ( 1.1 , 1.2 ) 1.1 Treatment of Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. 1.2 Treatment of Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Mechanism: Ciclesonide is a pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120-times higher than the parent compound. The precise mechanism through which ciclesonide affects allergic rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OMNARIS · CICLESONIDE 0.05MG/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciclesonide" as an intervention, any sponsor and status, largest first.

All 81 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthma1,876
  • dyspnoea1,500
  • wheezing1,439
  • therapeutic product effect incomplete1,057
  • obstructive airways disorder851
  • productive cough759
  • cough740
  • condition aggravated682
  • pneumonia654
  • full blood count abnormal614
  • drug ineffective596
  • sleep disorder due to a general medical condition588

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20073
200811
200943
201074
201168
2012112
201388
201499
2015157
2016237
2017186
2018220
2019435
2020609
2021728
2022459
2023355
2024426
2025391
2026296

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Omnaris (Ciclesonide)

2024 spending

$858K

Beneficiaries

590

1,855 claims

Per beneficiary

$1,455

$22.87 per unit

View as table
YearSpending
2020$1,515,154
2021$1,283,101
2022$1,168,070
2023$922,639
2024$858,296

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 139 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.